Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Why Shares of Regeneron Are Rising Thursday
12:08pm, Thursday, 23'rd Mar 2023
If Dupixent is approved to treat COPD, it will be the seventh indication for the drug. Regeneron's sales dropped 24% last year.
The Fed pivot is near, and yield curve inversion has likely peaked. That's usually bad news for stocks, this Fidelity strategist says.
11:49am, Thursday, 23'rd Mar 2023 MarketWatch
Jurrien Timmer, director of global macro at Fidelity Investments, looked at the intersection of yield-curve inversions and the stock market.
Why Are Stocks Up Today?
11:10am, Thursday, 23'rd Mar 2023
Stocks are up today as investors react to the latest news from the Federal Reverse concerning interest rate increases. The news traders are talking about is a 0.25% increase in interest rates.
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
10:43am, Thursday, 23'rd Mar 2023
Regeneron Pharmaceuticals (NASDAQ: REGN ) stock is on the rise Thursday after the company released its latest data on Dupixent. Dupixent is a drug candidate for treating adults on maximal standard-of-
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
10:20am, Thursday, 23'rd Mar 2023 Zacks Investment Research
Smart Beta ETF report for IBB
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
09:03am, Thursday, 23'rd Mar 2023
Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker
Coinbase' stock tumbles on SEC warning, while First Republic and Regeneron shares rally, and other stocks on the move
08:00am, Thursday, 23'rd Mar 2023
Here were some of the more active stocks in premarket trading on Thursday, a day after sharp losses on Wall Street after the Federal Reserve's latest interest rate hike:
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
06:00am, Thursday, 23'rd Mar 2023 GlobeNewswire Inc.
First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo
Regeneron (REGN) Gets Label Extension for Cholesterol Drug
06:15pm, Wednesday, 22'nd Mar 2023 Zacks Investment Research
Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.
Regeneron (REGN) Gets Label Extension for Cholesterol Drug
04:01pm, Wednesday, 22'nd Mar 2023
Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.
7 Value Stocks Worth Buying at These 52-Week Highs
03:46pm, Wednesday, 22'nd Mar 2023
With the market still digesting the tremors of the banking sector fallout, investors may want to consider compelling value stocks to buy, even those trading near their 52-week highs. True, investors o
Here's one for the battered bulls: the second-largest sector in the S&P 500 is stirring to life, says this strategist.
12:45pm, Wednesday, 22'nd Mar 2023 MarketWatch
Everyone is watching the banks, but what about healthcare. It's breaking out, says this strategist.
Regeneron (REGN) Gains But Lags Market: What You Should Know
10:15pm, Tuesday, 21'st Mar 2023 Zacks Investment Research
Regeneron (REGN) closed the most recent trading day at $759.76, moving +0.07% from the previous trading session.
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
10:04am, Tuesday, 21'st Mar 2023 Zacks Investment Research
Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
05:59am, Tuesday, 21'st Mar 2023 GlobeNewswire Inc.
Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity comp
